ES2660831T3 - Derivados de imidazol condensados útiles como inhibidores de IDO - Google Patents
Derivados de imidazol condensados útiles como inhibidores de IDO Download PDFInfo
- Publication number
- ES2660831T3 ES2660831T3 ES15197593.5T ES15197593T ES2660831T3 ES 2660831 T3 ES2660831 T3 ES 2660831T3 ES 15197593 T ES15197593 T ES 15197593T ES 2660831 T3 ES2660831 T3 ES 2660831T3
- Authority
- ES
- Spain
- Prior art keywords
- imidazo
- isoindol
- ethyl
- hydroxy
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 10
- 150000002460 imidazoles Chemical class 0.000 title description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title description 2
- -1 6-Chloro-5H-imidazo [5,1-a] isoindol-5-yl Chemical group 0.000 claims abstract description 182
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 18
- PESZLYAORBUEKU-UHFFFAOYSA-N 1-(2,4-dimethylfuran-3-yl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound CC1=COC(C)=C1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 PESZLYAORBUEKU-UHFFFAOYSA-N 0.000 claims abstract 4
- QRYSBXVPYUPWPS-UHFFFAOYSA-N 1-(2-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 QRYSBXVPYUPWPS-UHFFFAOYSA-N 0.000 claims abstract 4
- BMDIVHVHCUXCED-UHFFFAOYSA-N 1-(2-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound NC1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 BMDIVHVHCUXCED-UHFFFAOYSA-N 0.000 claims abstract 4
- FCJBROSAFICRIB-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound ClC1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 FCJBROSAFICRIB-UHFFFAOYSA-N 0.000 claims abstract 4
- KYSMLSSHZDKYMC-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC(Cl)=C1 KYSMLSSHZDKYMC-UHFFFAOYSA-N 0.000 claims abstract 4
- VVIHJLDHSORWDP-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound ClC1=CC=CC(C(=O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 VVIHJLDHSORWDP-UHFFFAOYSA-N 0.000 claims abstract 4
- CCWQDYPXEQFDAH-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC(N)=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 CCWQDYPXEQFDAH-UHFFFAOYSA-N 0.000 claims abstract 4
- JDTLXYAWWCQLKO-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1=CC(N)=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 JDTLXYAWWCQLKO-UHFFFAOYSA-N 0.000 claims abstract 4
- JNNMYZDYWKIDMJ-UHFFFAOYSA-N 1-(5h-imidazo[5,1-a]isoindol-5-yl)-2-methylpropan-2-ol Chemical compound C1=CC=C2C3=CN=CN3C(CC(C)(O)C)C2=C1 JNNMYZDYWKIDMJ-UHFFFAOYSA-N 0.000 claims abstract 4
- YTRRAUACYORZLX-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCCC1 YTRRAUACYORZLX-UHFFFAOYSA-N 0.000 claims abstract 4
- AKOIXTSNUPHRQM-UHFFFAOYSA-N 1-cyclohexyl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCCCC1 AKOIXTSNUPHRQM-UHFFFAOYSA-N 0.000 claims abstract 4
- RVUYIEVFJNWBDV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(2-nitrophenyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1[N+]([O-])=O RVUYIEVFJNWBDV-UHFFFAOYSA-N 0.000 claims abstract 4
- DIXRFDWKFCYQSI-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(2-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 DIXRFDWKFCYQSI-UHFFFAOYSA-N 0.000 claims abstract 4
- RLXCXBWRZHJHBP-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-nitrophenyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC([N+]([O-])=O)=C1 RLXCXBWRZHJHBP-UHFFFAOYSA-N 0.000 claims abstract 4
- MLYALVMQZHXKJU-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 MLYALVMQZHXKJU-UHFFFAOYSA-N 0.000 claims abstract 4
- JXTJKNFGBORUEK-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(oxan-4-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCOCC1 JXTJKNFGBORUEK-UHFFFAOYSA-N 0.000 claims abstract 4
- NVAQHNXPNVUNHA-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-phenylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1 NVAQHNXPNVUNHA-UHFFFAOYSA-N 0.000 claims abstract 4
- VQGLVXRSMONFQT-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical group C1=CC=C2C3=CN=CN3C(CCO)C2=C1 VQGLVXRSMONFQT-UHFFFAOYSA-N 0.000 claims abstract 4
- MYDKOCAYWGREPX-VVDNUDKFSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl 2-[(1r,2r,5s)-5-methyl-2-propan-2-ylcyclohexyl]oxyacetate Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@H]1OCC(=O)OCCC1N2C=NC=C2C2=CC=CC=C21 MYDKOCAYWGREPX-VVDNUDKFSA-N 0.000 claims abstract 4
- WRFXUJBZOJLWBB-UHFFFAOYSA-N ethyl 2-(5h-imidazo[5,1-a]isoindol-5-yl)acetate Chemical compound C1=CC=C2C3=CN=CN3C(CC(=O)OCC)C2=C1 WRFXUJBZOJLWBB-UHFFFAOYSA-N 0.000 claims abstract 4
- XSCIACOBOYKTCG-UHFFFAOYSA-N tert-butyl n-[2-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 XSCIACOBOYKTCG-UHFFFAOYSA-N 0.000 claims abstract 4
- BLMRVWKNYYFJNH-UHFFFAOYSA-N tert-butyl n-[2-[2-(5h-imidazo[5,1-a]isoindol-5-yl)acetyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 BLMRVWKNYYFJNH-UHFFFAOYSA-N 0.000 claims abstract 4
- ZOYUNVHKXHQRTI-UHFFFAOYSA-N tert-butyl n-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C(O)CC1N2C=NC=C2C2=CC=CC=C21 ZOYUNVHKXHQRTI-UHFFFAOYSA-N 0.000 claims abstract 4
- TTXRSWJNADPSSS-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=C1Cl TTXRSWJNADPSSS-UHFFFAOYSA-N 0.000 claims abstract 3
- IDAMUBBXWPKKDM-UHFFFAOYSA-N 1-cyclohexyl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanone Chemical compound C1=2C(F)=CC=CC=2C2=CN=CN2C1CC(=O)C1CCCCC1 IDAMUBBXWPKKDM-UHFFFAOYSA-N 0.000 claims abstract 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 239000001257 hydrogen Substances 0.000 claims description 65
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 57
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 57
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 43
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 35
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 27
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 150000002367 halogens Chemical group 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 206010062016 Immunosuppression Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 208000037765 diseases and disorders Diseases 0.000 claims description 4
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 50
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 21
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 18
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 15
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 9
- YGACXVRLDHEXKY-LHPNLFKDSA-N 4-[(1r)-2-[(5s)-6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1([C@@H](C[C@@H]2N3C=NC=C3C3=C2C(=CC=C3)F)O)CCC(O)CC1 YGACXVRLDHEXKY-LHPNLFKDSA-N 0.000 claims 7
- YTRRAUACYORZLX-WMZOPIPTSA-N (1s)-1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-WMZOPIPTSA-N 0.000 claims 6
- YQNFLDBZFLCLLR-JTHBVZDNSA-N 4-[(1r)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]-n-phenylpiperidine-1-carboxamide Chemical compound C1CC([C@@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)NC1=CC=CC=C1 YQNFLDBZFLCLLR-JTHBVZDNSA-N 0.000 claims 6
- YGACXVRLDHEXKY-LRBMDJJVSA-N 4-[(1r)-2-[(5r)-6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1([C@@H](C[C@H]2N3C=NC=C3C3=C2C(=CC=C3)F)O)CCC(O)CC1 YGACXVRLDHEXKY-LRBMDJJVSA-N 0.000 claims 6
- YGACXVRLDHEXKY-LHLWNEDTSA-N 4-[(1s)-2-[(5r)-6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1([C@H](C[C@H]2N3C=NC=C3C3=C2C(=CC=C3)F)O)CCC(O)CC1 YGACXVRLDHEXKY-LHLWNEDTSA-N 0.000 claims 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 6
- GGPLEOHHSWNDKN-UHFFFAOYSA-N n-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexyl]benzamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1NC(=O)C1=CC=CC=C1 GGPLEOHHSWNDKN-UHFFFAOYSA-N 0.000 claims 6
- YGACXVRLDHEXKY-VDPJLGHJSA-N 4-[(1s)-2-[(5s)-6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1([C@H](C[C@@H]2N3C=NC=C3C3=C2C(=CC=C3)F)O)CCC(O)CC1 YGACXVRLDHEXKY-VDPJLGHJSA-N 0.000 claims 5
- YTRRAUACYORZLX-UHUGOGIASA-N (1r)-1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1([C@@H](CC2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-UHUGOGIASA-N 0.000 claims 3
- YTRRAUACYORZLX-SJLPKXTDSA-N (1r)-1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-SJLPKXTDSA-N 0.000 claims 3
- YTRRAUACYORZLX-FUHWJXTLSA-N (1r)-1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-FUHWJXTLSA-N 0.000 claims 3
- YTRRAUACYORZLX-DAFXYXGESA-N (1s)-1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1([C@H](CC2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-DAFXYXGESA-N 0.000 claims 3
- YTRRAUACYORZLX-AEFFLSMTSA-N (1s)-1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C1([C@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCCCC1 YTRRAUACYORZLX-AEFFLSMTSA-N 0.000 claims 3
- KVZKINKUBBROSQ-ICXLUZGWSA-N (2s)-2-amino-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-3-phenylpropan-1-one Chemical compound C([C@H](N)C(=O)N1CCC(CC1)C(O)CC1N2C=NC=C2C2=CC=CC=C21)C1=CC=CC=C1 KVZKINKUBBROSQ-ICXLUZGWSA-N 0.000 claims 3
- FRFMOJJXJLFIDQ-UHFFFAOYSA-N (3-fluoro-2-hydroxyphenyl)-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=CC(F)=C1O FRFMOJJXJLFIDQ-UHFFFAOYSA-N 0.000 claims 3
- SBGDHJQZWJCENG-UHFFFAOYSA-N (4-fluorophenyl)-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=C(F)C=C1 SBGDHJQZWJCENG-UHFFFAOYSA-N 0.000 claims 3
- RRQRZNAPWJNCHH-MBIQTGHCSA-N (5s)-5-(2-cyclohexyl-2-hydroxyethyl)-5h-imidazo[5,1-a]isoindol-6-ol Chemical compound C([C@@H]1N2C=NC=C2C2=C1C(=CC=C2)O)C(O)C1CCCCC1 RRQRZNAPWJNCHH-MBIQTGHCSA-N 0.000 claims 3
- QJJZDVYBJWAXFJ-UHFFFAOYSA-N 1-(1-benzylsulfonylpiperidin-4-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1S(=O)(=O)CC1=CC=CC=C1 QJJZDVYBJWAXFJ-UHFFFAOYSA-N 0.000 claims 3
- WHXGLOURXNAWRM-UHFFFAOYSA-N 1-(2-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1CCCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 WHXGLOURXNAWRM-UHFFFAOYSA-N 0.000 claims 3
- AEXLPMGBOMVETQ-UHFFFAOYSA-N 1-(3-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1C(N)CCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 AEXLPMGBOMVETQ-UHFFFAOYSA-N 0.000 claims 3
- XKHZICCQURTELE-UHFFFAOYSA-N 1-(3-aminophenyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=CC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 XKHZICCQURTELE-UHFFFAOYSA-N 0.000 claims 3
- BBYFCKZHLMMOBN-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(F)(F)CC1 BBYFCKZHLMMOBN-UHFFFAOYSA-N 0.000 claims 3
- OWKPEYRNGTVBEN-UHFFFAOYSA-N 1-(4-aminocyclohexyl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(N)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 OWKPEYRNGTVBEN-UHFFFAOYSA-N 0.000 claims 3
- SXBYEDHYJLPXEQ-UHFFFAOYSA-N 1-(5h-imidazo[5,1-a]isoindol-5-yl)-3-methylbutan-2-ol Chemical compound C1=CC=C2C3=CN=CN3C(CC(O)C(C)C)C2=C1 SXBYEDHYJLPXEQ-UHFFFAOYSA-N 0.000 claims 3
- MRJBMWLOCDYCAN-UHFFFAOYSA-N 1-(cyclohexen-1-yl)-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CCCCC1 MRJBMWLOCDYCAN-UHFFFAOYSA-N 0.000 claims 3
- ZBLUTUCNUZUDLC-UHFFFAOYSA-N 1-[1-(4-aminopyrimidin-2-yl)piperidin-4-yl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=CC=NC(N2CCC(CC2)C(O)CC2N3C=NC=C3C3=CC=CC=C32)=N1 ZBLUTUCNUZUDLC-UHFFFAOYSA-N 0.000 claims 3
- XCPKPBVNKDRBNO-UHFFFAOYSA-N 1-[3-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]azetidin-1-yl]-2-phenylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(C1)CN1C(=O)CC1=CC=CC=C1 XCPKPBVNKDRBNO-UHFFFAOYSA-N 0.000 claims 3
- ORGKDAJDXPSGMH-UHFFFAOYSA-N 1-[4-(2-hydroxyethylidene)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(=CCO)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 ORGKDAJDXPSGMH-UHFFFAOYSA-N 0.000 claims 3
- ATEZPMBIQPSAPX-UHFFFAOYSA-N 1-[4-(aminomethyl)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1CC(CN)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 ATEZPMBIQPSAPX-UHFFFAOYSA-N 0.000 claims 3
- PRUMALLZQVUWMP-UHFFFAOYSA-N 1-[4-(cyclopropylmethylidene)cyclohexyl]-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1=CC1CC1 PRUMALLZQVUWMP-UHFFFAOYSA-N 0.000 claims 3
- NWDKPBHGOWJAIE-UHFFFAOYSA-N 1-[4-(difluoromethylidene)cyclohexyl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=C(F)F)CC1 NWDKPBHGOWJAIE-UHFFFAOYSA-N 0.000 claims 3
- YEBWNEBTTYUFMD-LADGPHEKSA-N 1-[4-[(1r)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidin-1-yl]-2-phenylethanone Chemical compound C1CC([C@@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)CC1=CC=CC=C1 YEBWNEBTTYUFMD-LADGPHEKSA-N 0.000 claims 3
- YEBWNEBTTYUFMD-UPVQGACJSA-N 1-[4-[(1s)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidin-1-yl]-2-phenylethanone Chemical compound C1CC([C@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)CC1=CC=CC=C1 YEBWNEBTTYUFMD-UPVQGACJSA-N 0.000 claims 3
- JTROHOGCUWMDID-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(2-methyl-1,3-thiazol-5-yl)ethanone Chemical compound S1C(C)=NC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 JTROHOGCUWMDID-UHFFFAOYSA-N 0.000 claims 3
- GRTMSCAOJVEIAZ-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(3-hydroxyphenyl)ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=CC(O)=C1 GRTMSCAOJVEIAZ-UHFFFAOYSA-N 0.000 claims 3
- QICFCOROQQCJFR-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(4-methylphenyl)ethanone Chemical compound C1=CC(C)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 QICFCOROQQCJFR-UHFFFAOYSA-N 0.000 claims 3
- RHYNNJXEEIIUOZ-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 RHYNNJXEEIIUOZ-UHFFFAOYSA-N 0.000 claims 3
- ADXRHXZIAQWYPA-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-pyridin-4-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=NC=C1 ADXRHXZIAQWYPA-UHFFFAOYSA-N 0.000 claims 3
- MQBRBOPIMMPJSH-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-3,3-dimethylbutan-1-one Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 MQBRBOPIMMPJSH-UHFFFAOYSA-N 0.000 claims 3
- TZLKQKCGJBWURI-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 TZLKQKCGJBWURI-UHFFFAOYSA-N 0.000 claims 3
- KNCOURWLVNPTET-UHFFFAOYSA-N 1-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]-3-phenylurea Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)NC1=CC=CC=C1 KNCOURWLVNPTET-UHFFFAOYSA-N 0.000 claims 3
- TXXNCTKTORUINM-UHFFFAOYSA-N 1-cyclohex-3-en-1-yl-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC=CC1 TXXNCTKTORUINM-UHFFFAOYSA-N 0.000 claims 3
- RFBQNUVWLVCPTH-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)-n-methylethanamine Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(NC)C1CCCCC1 RFBQNUVWLVCPTH-UHFFFAOYSA-N 0.000 claims 3
- OCMQWRLTHDLIRS-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanamine Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(N)C1CCCCC1 OCMQWRLTHDLIRS-UHFFFAOYSA-N 0.000 claims 3
- LXUFCLWCRAGUAS-UHFFFAOYSA-N 1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)propan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1C(C)C(O)C1CCCCC1 LXUFCLWCRAGUAS-UHFFFAOYSA-N 0.000 claims 3
- GZLGDNBVPZDDHN-UHFFFAOYSA-N 1-cyclohexyl-2-(8-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=C(F)C=C2C2=CN=CN2C1CC(O)C1CCCCC1 GZLGDNBVPZDDHN-UHFFFAOYSA-N 0.000 claims 3
- IKPLNLUUWHVZPW-UHFFFAOYSA-N 1-cyclohexyl-2-(9-methoxy-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound N12C=NC=C2C=2C(OC)=CC=CC=2C1CC(O)C1CCCCC1 IKPLNLUUWHVZPW-UHFFFAOYSA-N 0.000 claims 3
- YTRRAUACYORZLX-PYUWXLGESA-N 1-cyclohexyl-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C([C@H]1N2C=NC=C2C2=CC=CC=C21)C(O)C1CCCCC1 YTRRAUACYORZLX-PYUWXLGESA-N 0.000 claims 3
- YTRRAUACYORZLX-ATNAJCNCSA-N 1-cyclohexyl-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethanol Chemical compound C([C@@H]1N2C=NC=C2C2=CC=CC=C21)C(O)C1CCCCC1 YTRRAUACYORZLX-ATNAJCNCSA-N 0.000 claims 3
- JYHYESPWJNAVOK-UHFFFAOYSA-N 1-cyclohexyl-2-imidazo[1,5-b]isoindol-5-ylideneethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1=CC(O)C1CCCCC1 JYHYESPWJNAVOK-UHFFFAOYSA-N 0.000 claims 3
- QYPGWMMBPPVTDC-UHFFFAOYSA-N 1-cyclohexyl-3-(5h-imidazo[5,1-a]isoindol-5-yl)propan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CCC(O)C1CCCCC1 QYPGWMMBPPVTDC-UHFFFAOYSA-N 0.000 claims 3
- VXLCRYSJAYJVGS-UHFFFAOYSA-N 1-cyclohexyl-3-(5h-imidazo[5,1-a]isoindol-5-yl)propan-2-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)CC1CCCCC1 VXLCRYSJAYJVGS-UHFFFAOYSA-N 0.000 claims 3
- OBBNZIWTQPASCP-UHFFFAOYSA-N 1-cyclohexyl-3-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)propan-2-ol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)CC1CCCCC1 OBBNZIWTQPASCP-UHFFFAOYSA-N 0.000 claims 3
- WRGKBSDYTGFYGX-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(F)C(F)=C1 WRGKBSDYTGFYGX-UHFFFAOYSA-N 0.000 claims 3
- GCUYSCRDNLRJNF-UHFFFAOYSA-N 2-(4-fluorophenyl)-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(F)C=C1 GCUYSCRDNLRJNF-UHFFFAOYSA-N 0.000 claims 3
- VBGYBTPGGDXLMD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-4-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CSC=N1 VBGYBTPGGDXLMD-UHFFFAOYSA-N 0.000 claims 3
- XGPDPODYEGNQHX-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CN=CS1 XGPDPODYEGNQHX-UHFFFAOYSA-N 0.000 claims 3
- DLWAENXUQXYBMY-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1h-imidazol-2-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=NC=CN1 DLWAENXUQXYBMY-UHFFFAOYSA-N 0.000 claims 3
- INGRTMFZXCULBB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(1h-imidazol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CNC=N1 INGRTMFZXCULBB-UHFFFAOYSA-N 0.000 claims 3
- VVBPUZHWIHLPDF-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=C)CC1 VVBPUZHWIHLPDF-UHFFFAOYSA-N 0.000 claims 3
- NGSMNKAYPOQDKS-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[1-(2-phenylethanimidoyl)piperidin-4-yl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=N)CC1=CC=CC=C1 NGSMNKAYPOQDKS-UHFFFAOYSA-N 0.000 claims 3
- FLGBJLSDZNXFTD-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(1,3-oxazol-2-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1=NC=CO1 FLGBJLSDZNXFTD-UHFFFAOYSA-N 0.000 claims 3
- HHNUPFRQCKGATB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(1,3-thiazol-2-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1=NC=CS1 HHNUPFRQCKGATB-UHFFFAOYSA-N 0.000 claims 3
- PDXQXGJDMVXEOS-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(2,2,2-trifluoroethylidene)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=CC(F)(F)F)CC1 PDXQXGJDMVXEOS-UHFFFAOYSA-N 0.000 claims 3
- LEJRMYUCBJPDLO-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(2-phenylmethoxyethylidene)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1=CCOCC1=CC=CC=C1 LEJRMYUCBJPDLO-UHFFFAOYSA-N 0.000 claims 3
- OZXLCOHVTZVPNC-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(oxan-4-ylmethoxy)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC1OCC1CCOCC1 OZXLCOHVTZVPNC-UHFFFAOYSA-N 0.000 claims 3
- DXHZTNYHUDMHMF-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(C(F)(F)F)CC1 DXHZTNYHUDMHMF-UHFFFAOYSA-N 0.000 claims 3
- QSCNULJNJWIRQZ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-piperidin-3-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCNC1 QSCNULJNJWIRQZ-UHFFFAOYSA-N 0.000 claims 3
- FNGDHPYZIOFVLB-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-2-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CC=N1 FNGDHPYZIOFVLB-UHFFFAOYSA-N 0.000 claims 3
- JNVJGLYGJXLWMV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-3-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=CN=C1 JNVJGLYGJXLWMV-UHFFFAOYSA-N 0.000 claims 3
- RLYSBDKKQFJXQY-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-pyridin-4-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1=CC=NC=C1 RLYSBDKKQFJXQY-UHFFFAOYSA-N 0.000 claims 3
- SMPOUDVZNQHGAJ-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-spiro[2.5]octan-6-ylethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCC21CC2 SMPOUDVZNQHGAJ-UHFFFAOYSA-N 0.000 claims 3
- FEUNICQQIZEYDV-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)acetonitrile Chemical compound C1=CC=C2C3=CN=CN3C(CC#N)C2=C1 FEUNICQQIZEYDV-UHFFFAOYSA-N 0.000 claims 3
- INSWVLVOFHQFIC-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(1,3-thiazol-2-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1=NC=CS1 INSWVLVOFHQFIC-UHFFFAOYSA-N 0.000 claims 3
- CHTSIMRFIJVBCC-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(1-methylpiperidin-4-yl)ethanol Chemical compound C1CN(C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 CHTSIMRFIJVBCC-UHFFFAOYSA-N 0.000 claims 3
- SHRFEOBHMXWKSI-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(3-methylimidazol-4-yl)ethanol Chemical compound CN1C=NC=C1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 SHRFEOBHMXWKSI-UHFFFAOYSA-N 0.000 claims 3
- KMIOWWHRINGLFM-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanol Chemical compound C1CC(C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 KMIOWWHRINGLFM-UHFFFAOYSA-N 0.000 claims 3
- SCWXAHFBXGCWHC-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-phenylmethoxycyclohexyl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1OCC1=CC=CC=C1 SCWXAHFBXGCWHC-UHFFFAOYSA-N 0.000 claims 3
- PMNBNUNUHZZMCV-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-propan-2-ylidenecyclohexyl)ethanol Chemical compound C1CC(=C(C)C)CCC1C(O)CC1N2C=NC=C2C2=C1C(F)=CC=C2 PMNBNUNUHZZMCV-UHFFFAOYSA-N 0.000 claims 3
- TYYSLXOKEGQSTO-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(iodomethylidene)cyclohexyl]ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=CI)CC1 TYYSLXOKEGQSTO-UHFFFAOYSA-N 0.000 claims 3
- YQEVXFURUXEILY-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-[4-(trifluoromethyl)cyclohexyl]ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(C(F)(F)F)CC1 YQEVXFURUXEILY-UHFFFAOYSA-N 0.000 claims 3
- CLBMXXZZZNDZBL-UHFFFAOYSA-N 2-(9-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylcyclohexyl)ethanol Chemical compound C1CC(C)CCC1C(O)CC1N2C=NC=C2C2=C(F)C=CC=C21 CLBMXXZZZNDZBL-UHFFFAOYSA-N 0.000 claims 3
- IDIMZVATARIKGW-UHFFFAOYSA-N 2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexylidene]acetonitrile Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(=CC#N)CC1 IDIMZVATARIKGW-UHFFFAOYSA-N 0.000 claims 3
- YXPVIJYOABHAIM-UHFFFAOYSA-N 2-cyclopentyl-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1CCCC1 YXPVIJYOABHAIM-UHFFFAOYSA-N 0.000 claims 3
- GOTWJZVRVPDDMN-UHFFFAOYSA-N 2-cyclopropyl-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]ethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1CC1 GOTWJZVRVPDDMN-UHFFFAOYSA-N 0.000 claims 3
- SHXUOYHQIRNOEI-UHFFFAOYSA-N 3-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]-n-phenylazetidine-1-carboxamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(C1)CN1C(=O)NC1=CC=CC=C1 SHXUOYHQIRNOEI-UHFFFAOYSA-N 0.000 claims 3
- YQNFLDBZFLCLLR-FYYLOGMGSA-N 4-[(1r)-1-hydroxy-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]-n-phenylpiperidine-1-carboxamide Chemical compound C1CC([C@@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)NC1=CC=CC=C1 YQNFLDBZFLCLLR-FYYLOGMGSA-N 0.000 claims 3
- YQNFLDBZFLCLLR-GGAORHGYSA-N 4-[(1s)-1-hydroxy-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]-n-phenylpiperidine-1-carboxamide Chemical compound C1CC([C@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)NC1=CC=CC=C1 YQNFLDBZFLCLLR-GGAORHGYSA-N 0.000 claims 3
- KECJSORXVGLSAH-UHFFFAOYSA-N 4-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethoxy]-4-oxobutanoic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)CCC(=O)O)C1CCCCC1 KECJSORXVGLSAH-UHFFFAOYSA-N 0.000 claims 3
- KHRSALHCWRYRRN-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]-n'-phenylpiperidine-1-carboximidamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=N)NC1=CC=CC=C1 KHRSALHCWRYRRN-UHFFFAOYSA-N 0.000 claims 3
- YQNFLDBZFLCLLR-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]-n-phenylpiperidine-1-carboxamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)NC1=CC=CC=C1 YQNFLDBZFLCLLR-UHFFFAOYSA-N 0.000 claims 3
- JIVGYYJPJKYZPP-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexan-1-ol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(O)CC1 JIVGYYJPJKYZPP-UHFFFAOYSA-N 0.000 claims 3
- AVUZOXPRZPEVIP-UHFFFAOYSA-N 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexane-1-carboxylic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC(C(O)=O)CC1 AVUZOXPRZPEVIP-UHFFFAOYSA-N 0.000 claims 3
- VISMIBIBEYHWCU-UHFFFAOYSA-N 4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]-n-phenylcyclohexane-1-carboxamide Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1C(=O)NC1=CC=CC=C1 VISMIBIBEYHWCU-UHFFFAOYSA-N 0.000 claims 3
- YGACXVRLDHEXKY-UHFFFAOYSA-N 4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(O)CC1 YGACXVRLDHEXKY-UHFFFAOYSA-N 0.000 claims 3
- OYGJBQURZPTNSK-UHFFFAOYSA-N 4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexan-1-one Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=O)CC1 OYGJBQURZPTNSK-UHFFFAOYSA-N 0.000 claims 3
- YGACXVRLDHEXKY-IQGLFJIHSA-N 4-[2-[(5s)-6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol Chemical compound C([C@@H]1N2C=NC=C2C2=C1C(=CC=C2)F)C(O)C1CCC(O)CC1 YGACXVRLDHEXKY-IQGLFJIHSA-N 0.000 claims 3
- BHKLFTQVVMYRAH-UHFFFAOYSA-N 4-[2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-oxoethyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 BHKLFTQVVMYRAH-UHFFFAOYSA-N 0.000 claims 3
- NSQXEQFBHZFTES-UHFFFAOYSA-N 4-[2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-oxoethyl]benzoic acid Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CC=C(C(O)=O)C=C1 NSQXEQFBHZFTES-UHFFFAOYSA-N 0.000 claims 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 3
- YUHFEKHIZVIKIR-UHFFFAOYSA-N 5-(2-cyclohexyl-2-hydroxyethyl)-5h-imidazo[5,1-a]isoindol-9-ol Chemical compound C12=CC=CC(O)=C2C2=CN=CN2C1CC(O)C1CCCCC1 YUHFEKHIZVIKIR-UHFFFAOYSA-N 0.000 claims 3
- DFYHDIYAMRTKAI-ZHACJKMWSA-N 5-[(e)-2-cyclohexylethenyl]-5h-imidazo[5,1-a]isoindole Chemical compound C1CCCCC1\C=C\C1N2C=NC=C2C2=CC=CC=C21 DFYHDIYAMRTKAI-ZHACJKMWSA-N 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 3
- WPVMUROBGLEYFB-KLOIUYPJSA-N [1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] (2s)-2-aminopropanoate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)[C@@H](N)C)C1CCCCC1 WPVMUROBGLEYFB-KLOIUYPJSA-N 0.000 claims 3
- HVZJGGWTHITDQX-UHFFFAOYSA-N [1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] acetate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)C)C1CCCCC1 HVZJGGWTHITDQX-UHFFFAOYSA-N 0.000 claims 3
- JOYFFDTXFJNFLT-UHFFFAOYSA-N [1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] n-phenylcarbamate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(C1CCCCC1)OC(=O)NC1=CC=CC=C1 JOYFFDTXFJNFLT-UHFFFAOYSA-N 0.000 claims 3
- QXDJDTDEBGGFGH-UHFFFAOYSA-N [2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-[1-(phenylcarbamoyl)piperidin-4-yl]ethyl] n-phenylcarbamate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(C1CCN(CC1)C(=O)NC=1C=CC=CC=1)OC(=O)NC1=CC=CC=C1 QXDJDTDEBGGFGH-UHFFFAOYSA-N 0.000 claims 3
- XKYDXVDTWDQCAV-JSOIOWGOSA-N [4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-[(2s)-pyrrolidin-2-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)[C@@H]1CCCN1 XKYDXVDTWDQCAV-JSOIOWGOSA-N 0.000 claims 3
- HIFKHTGNHWXMNH-UHFFFAOYSA-N [4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-thiophen-2-ylmethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1=CC=CS1 HIFKHTGNHWXMNH-UHFFFAOYSA-N 0.000 claims 3
- NTBNOWXFZMDXDZ-UHFFFAOYSA-N [4-[2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl] benzoate Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1OC(=O)C1=CC=CC=C1 NTBNOWXFZMDXDZ-UHFFFAOYSA-N 0.000 claims 3
- FDUHADIZUWTWAZ-UHFFFAOYSA-N cyclohexyl-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]methanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)C1CCCCC1 FDUHADIZUWTWAZ-UHFFFAOYSA-N 0.000 claims 3
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims 3
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 3
- PJZVULFUQSLZMW-UHFFFAOYSA-N methyl 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexane-1-carboxylate Chemical compound C1CC(C(=O)OC)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 PJZVULFUQSLZMW-UHFFFAOYSA-N 0.000 claims 3
- KJACTJCUOAPGNQ-UHFFFAOYSA-N n-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]acetamide Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(NC(=O)C)C1CCCCC1 KJACTJCUOAPGNQ-UHFFFAOYSA-N 0.000 claims 3
- MMUUOCZEFMSKGV-UHFFFAOYSA-N n-[2-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexyl]acetamide Chemical compound CC(=O)NC1CCCCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 MMUUOCZEFMSKGV-UHFFFAOYSA-N 0.000 claims 3
- XGXIYSFXMYLWCL-UHFFFAOYSA-N n-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]cyclohexyl]acetamide Chemical compound C1CC(NC(=O)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 XGXIYSFXMYLWCL-UHFFFAOYSA-N 0.000 claims 3
- MLIIRCUDJAEHTO-UHFFFAOYSA-N n-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]-2-phenylacetamide Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)CC1=CC=CC=C1 MLIIRCUDJAEHTO-UHFFFAOYSA-N 0.000 claims 3
- HBHJJHJDVFXZGH-UHFFFAOYSA-N n-[4-[2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl]cyclohexyl]benzamide Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C(CC1)CCC1NC(=O)C1=CC=CC=C1 HBHJJHJDVFXZGH-UHFFFAOYSA-N 0.000 claims 3
- IEHATHSCQGVOMX-UHFFFAOYSA-N n-[4-[2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-oxoethyl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 IEHATHSCQGVOMX-UHFFFAOYSA-N 0.000 claims 3
- 239000010452 phosphate Substances 0.000 claims 3
- QUUYRYYUKNNNNS-UHFFFAOYSA-N piperidine-1-carboximidamide Chemical compound NC(=N)N1CCCCC1 QUUYRYYUKNNNNS-UHFFFAOYSA-N 0.000 claims 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- QYRWUEOAQAHUBN-UYAOXDASSA-N tert-butyl 4-[(1r)-1-hydroxy-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1[C@H](O)C[C@H]1N2C=NC=C2C2=CC=CC=C21 QYRWUEOAQAHUBN-UYAOXDASSA-N 0.000 claims 3
- QYRWUEOAQAHUBN-UHFFFAOYSA-N tert-butyl 4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 QYRWUEOAQAHUBN-UHFFFAOYSA-N 0.000 claims 3
- FJLIHIOROQHOOQ-UHFFFAOYSA-N tert-butyl n-[3-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)=C1 FJLIHIOROQHOOQ-UHFFFAOYSA-N 0.000 claims 3
- PPEUMDWFICZDCN-SILNSSARSA-N (nz)-n-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethylidene]hydroxylamine Chemical compound C12=CC=CC=C2C2=CN=CN2C1C/C(=N/O)C1CCCCC1 PPEUMDWFICZDCN-SILNSSARSA-N 0.000 claims 2
- FPKRCRNJVIHTNG-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(F)(F)CC1 FPKRCRNJVIHTNG-UHFFFAOYSA-N 0.000 claims 2
- UDZRVINHNLAGCI-UHFFFAOYSA-N 1-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C=1N=CN2C1C1=CC=CC=C1C2C(C)O UDZRVINHNLAGCI-UHFFFAOYSA-N 0.000 claims 2
- ISCDNERVCHFOSZ-UHFFFAOYSA-N 1-[1-(2-aminopyrimidin-4-yl)piperidin-4-yl]-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound NC1=NC=CC(N2CCC(CC2)C(O)CC2N3C=NC=C3C3=CC=CC=C32)=N1 ISCDNERVCHFOSZ-UHFFFAOYSA-N 0.000 claims 2
- BHPMBGLATDMBIK-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2,2-dimethylpropan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 BHPMBGLATDMBIK-UHFFFAOYSA-N 0.000 claims 2
- DUECNPBMYIFWGD-UHFFFAOYSA-N 1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-pyrimidin-5-ylethanone Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C(CC1)CCN1C(=O)CC1=CN=CN=C1 DUECNPBMYIFWGD-UHFFFAOYSA-N 0.000 claims 2
- UYEVJNPAUYAELH-UHFFFAOYSA-N 1-cyclohex-3-en-1-yl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCC=CC1 UYEVJNPAUYAELH-UHFFFAOYSA-N 0.000 claims 2
- OSGALIUMFAKSAR-UHFFFAOYSA-N 1-cyclohexyl-2-(9-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC(F)=C2C2=CN=CN2C1CC(O)C1CCCCC1 OSGALIUMFAKSAR-UHFFFAOYSA-N 0.000 claims 2
- MTNKITWGIJLVJD-UHFFFAOYSA-N 1-cyclopentyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCC1 MTNKITWGIJLVJD-UHFFFAOYSA-N 0.000 claims 2
- OHBRKNAYFFVLGG-UHFFFAOYSA-N 2-(5h-imidazo[5,1-a]isoindol-5-yl)-1-(oxan-3-yl)ethanol Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(O)C1CCCOC1 OHBRKNAYFFVLGG-UHFFFAOYSA-N 0.000 claims 2
- KBIQFEDIQLEELY-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(4-methylidenecyclohexyl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1CCC(=C)CC1 KBIQFEDIQLEELY-UHFFFAOYSA-N 0.000 claims 2
- NDSJYFMKCXEXFW-UHFFFAOYSA-N 2-(6-fluoro-5h-imidazo[5,1-a]isoindol-5-yl)-1-(furan-2-yl)ethanol Chemical compound C1=CC=C(F)C2=C1C1=CN=CN1C2CC(O)C1=CC=CO1 NDSJYFMKCXEXFW-UHFFFAOYSA-N 0.000 claims 2
- RDRKTEAOMSPEIT-UHFFFAOYSA-N 3,3-difluoro-1-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]butan-1-one Chemical compound C1CN(C(=O)CC(F)(F)C)CCC1C(O)CC1N2C=NC=C2C2=CC=CC=C21 RDRKTEAOMSPEIT-UHFFFAOYSA-N 0.000 claims 2
- YQNFLDBZFLCLLR-GMAHTHKFSA-N 4-[(1s)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]-n-phenylpiperidine-1-carboxamide Chemical compound C1CC([C@H](C[C@@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)NC1=CC=CC=C1 YQNFLDBZFLCLLR-GMAHTHKFSA-N 0.000 claims 2
- LBQMOMOJHCUWOK-UHFFFAOYSA-N 4-[2-[4-[1-hydroxy-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl]piperidin-1-yl]-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC(=O)N1CCC(C(O)CC2N3C=NC=C3C3=CC=CC=C32)CC1 LBQMOMOJHCUWOK-UHFFFAOYSA-N 0.000 claims 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- QYRWUEOAQAHUBN-QUCCMNQESA-N tert-butyl 4-[(1s)-1-hydroxy-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1[C@@H](O)C[C@H]1N2C=NC=C2C2=CC=CC=C21 QYRWUEOAQAHUBN-QUCCMNQESA-N 0.000 claims 2
- QYRWUEOAQAHUBN-ICSRJNTNSA-N tert-butyl 4-[(1s)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1[C@@H](O)C[C@@H]1N2C=NC=C2C2=CC=CC=C21 QYRWUEOAQAHUBN-ICSRJNTNSA-N 0.000 claims 2
- HMWJTYJOWMVDLR-UHFFFAOYSA-N tert-butyl n-[4-[2-(5h-imidazo[5,1-a]isoindol-5-yl)acetyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C(=O)CC1N2C=NC=C2C2=CC=CC=C21 HMWJTYJOWMVDLR-UHFFFAOYSA-N 0.000 claims 2
- YEBWNEBTTYUFMD-ISKFKSNPSA-N 1-[4-[(1r)-1-hydroxy-2-[(5r)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidin-1-yl]-2-phenylethanone Chemical compound C1CC([C@@H](C[C@H]2N3C=NC=C3C3=CC=CC=C32)O)CCN1C(=O)CC1=CC=CC=C1 YEBWNEBTTYUFMD-ISKFKSNPSA-N 0.000 claims 1
- UKFHFLJKSPYLED-YMISUZCDSA-N 5-o-[1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] 1-o-methyl (2s)-2-aminopentanedioate Chemical compound C12=CC=CC=C2C2=CN=CN2C1CC(OC(=O)CC[C@H](N)C(=O)OC)C1CCCCC1 UKFHFLJKSPYLED-YMISUZCDSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- IECLZDAWLOZWSL-UHFFFAOYSA-N [1-cyclohexyl-2-(5h-imidazo[5,1-a]isoindol-5-yl)ethyl] benzoate Chemical compound C=1C=CC=CC=1C(=O)OC(CC1N2C=NC=C2C2=CC=CC=C21)C1CCCCC1 IECLZDAWLOZWSL-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- SEWIYICDCVPBEW-UHFFFAOYSA-N methyl glutamate Chemical compound COC(=O)C(N)CCC(O)=O SEWIYICDCVPBEW-UHFFFAOYSA-N 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- QYRWUEOAQAHUBN-AZUAARDMSA-N tert-butyl 4-[(1r)-1-hydroxy-2-[(5s)-5h-imidazo[5,1-a]isoindol-5-yl]ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1[C@H](O)C[C@@H]1N2C=NC=C2C2=CC=CC=C21 QYRWUEOAQAHUBN-AZUAARDMSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 description 23
- 125000000392 cycloalkenyl group Chemical group 0.000 description 18
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 229960004799 tryptophan Drugs 0.000 description 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- AWLWPSSHYJQPCH-VIFPVBQESA-N (2s)-2-amino-3-(6-nitro-1h-indol-3-yl)propanoic acid Chemical compound [O-][N+](=O)C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 AWLWPSSHYJQPCH-VIFPVBQESA-N 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101100406515 Drosophila melanogaster orb2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 101100258025 Schizosaccharomyces pombe (strain 972 / ATCC 24843) shk1 gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000003046 intermediate neglect of differential overlap Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475788P | 2011-04-15 | 2011-04-15 | |
| US201161475788P | 2011-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2660831T3 true ES2660831T3 (es) | 2018-03-26 |
Family
ID=45976556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15197593.5T Active ES2660831T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
| ES12715295.7T Active ES2569665T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12715295.7T Active ES2569665T3 (es) | 2011-04-15 | 2012-04-12 | Derivados de imidazol condensados útiles como inhibidores de IDO |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9260434B2 (enExample) |
| EP (3) | EP3348558A1 (enExample) |
| JP (4) | JP2014511876A (enExample) |
| KR (1) | KR102164443B1 (enExample) |
| CN (2) | CN103547579B (enExample) |
| AU (4) | AU2012242871C1 (enExample) |
| BR (1) | BR112013026494A2 (enExample) |
| CA (1) | CA2833296C (enExample) |
| CL (1) | CL2013002990A1 (enExample) |
| CO (1) | CO6862146A2 (enExample) |
| CY (1) | CY1117440T1 (enExample) |
| DK (2) | DK2697227T3 (enExample) |
| ES (2) | ES2660831T3 (enExample) |
| HK (1) | HK1256355A1 (enExample) |
| HR (2) | HRP20160369T1 (enExample) |
| HU (2) | HUE027316T2 (enExample) |
| IL (3) | IL228862A (enExample) |
| LT (1) | LT3018132T (enExample) |
| ME (1) | ME02417B (enExample) |
| MX (1) | MX340442B (enExample) |
| NO (1) | NO2694640T3 (enExample) |
| NZ (2) | NZ708090A (enExample) |
| PE (2) | PE20181023A1 (enExample) |
| PL (2) | PL3018132T3 (enExample) |
| PT (1) | PT3018132T (enExample) |
| RS (2) | RS54723B1 (enExample) |
| RU (2) | RU2613579C2 (enExample) |
| SI (2) | SI3018132T1 (enExample) |
| SM (1) | SMT201600130B (enExample) |
| WO (1) | WO2012142237A1 (enExample) |
Families Citing this family (282)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (enExample) * | 2011-04-15 | 2018-03-17 | ||
| EP2729180B1 (en) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| BR112015022588A2 (pt) | 2013-03-14 | 2017-07-18 | Newlink Genetics Corp | composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo |
| EA201591610A1 (ru) * | 2013-03-14 | 2015-12-30 | Курадев Фарма Прайвит Лтд. | Ингибиторы кинуренинового пути |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN103382187B (zh) * | 2013-08-06 | 2015-06-03 | 信实生物医药（上海）有限公司 | 一种3-氯-7(5)-溴苯并异恶唑的合成方法 |
| EA201990240A1 (ru) | 2013-12-24 | 2019-06-28 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| ES2901705T3 (es) | 2014-06-06 | 2022-03-23 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos |
| KR20170044144A (ko) | 2014-09-05 | 2017-04-24 | 메르크 파텐트 게엠베하 | 암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물 |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| GB201418300D0 (en) * | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| CA3220466A1 (en) | 2014-10-29 | 2016-05-06 | Bicyclerd Limited | Bicyclic peptide ligands specific for mt1-mmp |
| SI3221363T1 (sl) | 2014-11-21 | 2020-09-30 | Bristol-Myers Squibb Company | Protitelesa proti CD73 in njihova uporaba |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
| CA2971732A1 (en) | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
| US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| KR20170122799A (ko) | 2015-03-02 | 2017-11-06 | 리겔 파마슈티칼스, 인크. | TGF-β 억제제 |
| US10399933B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
| WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| KR20170137165A (ko) * | 2015-04-10 | 2017-12-12 | 베이진 엘티디 | 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘 |
| EP3283488A4 (en) * | 2015-04-12 | 2018-10-24 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as ido and tdo inhibitors |
| HUE053903T2 (hu) | 2015-04-13 | 2021-07-28 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| AU2016250976B2 (en) | 2015-04-21 | 2020-02-27 | Jiangsu Hengrui Medicine Co., Ltd. | Imidazo isoindole derivative, preparation method therefor and medical use thereof |
| WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| WO2016183115A1 (en) | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| CN106256830B (zh) * | 2015-06-18 | 2019-03-08 | 成都海创药业有限公司 | 一种氘代的ido抑制剂及其制备方法和用途 |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
| GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| MX2018001014A (es) | 2015-07-24 | 2018-05-23 | Newlink Genetics Corp | Sales y profarmacos de 1-metil-d-triptofano. |
| WO2017019757A1 (en) | 2015-07-28 | 2017-02-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| JP2018525415A (ja) | 2015-08-25 | 2018-09-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｇｆベータ受容体アンタゴニスト |
| CN106478634B (zh) * | 2015-09-01 | 2020-05-22 | 尚华医药科技(江西)有限公司 | 稠合咪唑化合物、其制备方法、药物组合物和用途 |
| WO2017075341A1 (en) * | 2015-10-29 | 2017-05-04 | Scifluor Life Sciences, Inc. | Fused imidazole derivatives as ido/tdo inhibitors |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| WO2017080934A1 (en) * | 2015-11-09 | 2017-05-18 | F. Hoffmann-La Roche Ag | Screening assay to identify id01 and/or tdo modulators |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| JP7349787B2 (ja) | 2015-11-23 | 2023-09-25 | ファイヴ プライム セラピューティクス インク | 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ |
| US10450318B2 (en) | 2015-12-15 | 2019-10-22 | Bristol-Myers Squibb Company | CXCR4 receptor antagonists |
| JP7227005B2 (ja) * | 2015-12-24 | 2023-02-21 | ジェネンテック， インコーポレイテッド | Ｔｄｏ２阻害剤 |
| CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| EP3400226A1 (en) | 2016-02-02 | 2018-11-14 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
| US10487088B2 (en) | 2016-02-19 | 2019-11-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tricyclic compound serving as immunomodulator |
| EP3416725A1 (en) | 2016-02-19 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| CN108884104B (zh) * | 2016-02-19 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 作为免疫调节剂的三并环化合物 |
| WO2017149469A1 (en) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Heterocyclic compounds useful as ido and/or tdo modulators |
| KR20230038311A (ko) | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| SG11201808821WA (en) | 2016-04-18 | 2018-11-29 | Celldex Therapeutics Inc | Agonistic antibodies that bind human cd40 and uses thereof |
| CN105732643A (zh) * | 2016-04-18 | 2016-07-06 | 苏州大学 | 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用 |
| CN107312005B (zh) * | 2016-04-27 | 2021-12-17 | 上海翰森生物医药科技有限公司 | 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用 |
| CN109348714A (zh) | 2016-05-04 | 2019-02-15 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| KR20190004743A (ko) | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| WO2017192813A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR20190003687A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| KR20190003686A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN105902542A (zh) * | 2016-05-16 | 2016-08-31 | 张阳 | 一种偶联物在制备治疗心血管疾病药物中的应用 |
| CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
| CN107556316B (zh) * | 2016-06-30 | 2021-11-12 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| WO2017198159A1 (zh) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | 含桥环的咪唑衍生物 |
| CN106957318B (zh) * | 2016-05-19 | 2019-12-10 | 中国科学院上海有机化学研究所 | 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用 |
| JP7090034B2 (ja) | 2016-05-20 | 2022-06-23 | ザ ユニバーシティ オブ シカゴ | 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子 |
| AR108586A1 (es) | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
| CN107488179B (zh) * | 2016-06-11 | 2024-06-07 | 鲁南制药集团股份有限公司 | 含桥环的咪唑醇衍生物 |
| CN107556315B (zh) * | 2016-06-30 | 2021-08-31 | 鲁南制药集团股份有限公司 | 含四元环的咪唑衍生物 |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| CN107698594A (zh) * | 2016-08-09 | 2018-02-16 | 苏州国匡医药科技有限公司 | 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途 |
| US11351164B2 (en) | 2016-08-26 | 2022-06-07 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2018045966A1 (zh) * | 2016-09-12 | 2018-03-15 | 广州必贝特医药技术有限公司 | 含咪唑稠合三环类化合物及其应用 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| CN109952300B (zh) | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
| AU2017343780B2 (en) | 2016-10-13 | 2023-08-31 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| TW201815793A (zh) * | 2016-10-21 | 2018-05-01 | 江蘇恆瑞醫藥股份有限公司 | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 |
| TW201815417A (zh) * | 2016-10-21 | 2018-05-01 | 蘇州盛迪亞生物醫藥有限公司 | Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途 |
| WO2018083635A2 (en) | 2016-11-04 | 2018-05-11 | Auckland Uniservices Limited | Tricyclic heterocyclic derivatives and uses thereof |
| CN106474468B (zh) * | 2016-11-23 | 2020-03-27 | 中国医学科学院医学生物学研究所 | 一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法 |
| WO2018106579A1 (en) * | 2016-12-06 | 2018-06-14 | Albert Einstein College Of Medicine, Inc. | Drug targeting of human indoleamine 2,3-dioxygenase |
| US10604529B2 (en) | 2016-12-20 | 2020-03-31 | Shenzhen Chipscreen Biosciences Co., Ltd. | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity |
| PE20191541A1 (es) | 2016-12-22 | 2019-10-23 | Calithera Biosciences Inc | Composiciones y metodos para inhibir la accion de la arginasa |
| CN108239091B (zh) * | 2016-12-26 | 2021-08-13 | 中国医学科学院药物研究所 | 1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分 |
| US10961239B2 (en) | 2017-01-05 | 2021-03-30 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| WO2018175954A1 (en) | 2017-03-23 | 2018-09-27 | F. Hoffmann-La Roche Ag | Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors |
| CA3057687A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| ES2899616T3 (es) | 2017-04-28 | 2022-03-14 | Five Prime Therapeutics Inc | Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central |
| WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN107176956B (zh) * | 2017-05-31 | 2019-11-12 | 成都海博锐药业有限公司 | 一种ido抑制剂化合物、药用组合物、用途 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019005559A1 (en) | 2017-06-28 | 2019-01-03 | Genentech, Inc. | INHIBITORS OF TDO2 AND IDO1 |
| US11827639B2 (en) | 2017-06-28 | 2023-11-28 | Genentech, Inc. | TDO2 and IDO1 inhibitors |
| US11236049B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of IDO inhibitors |
| KR102709265B1 (ko) | 2017-07-28 | 2024-09-23 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| CN111194232B (zh) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | 纳米级金属有机层和金属有机纳米片 |
| US11261214B2 (en) | 2017-08-04 | 2022-03-01 | Bicycletx Limited | Bicyclic peptide ligand specific for CD137 |
| CN109983019B (zh) * | 2017-08-08 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物的制备方法 |
| CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
| EP3668880B1 (en) | 2017-08-17 | 2021-10-06 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| CA3073051A1 (en) | 2017-08-17 | 2019-02-21 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| EP3670518A4 (en) | 2017-08-18 | 2021-01-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TRICYCLIC COMPOUND CRYSTALS |
| JP7209697B2 (ja) | 2017-08-31 | 2023-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| EP3676279B1 (en) | 2017-08-31 | 2021-12-01 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP3676277A1 (en) | 2017-08-31 | 2020-07-08 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| CN107501272B (zh) * | 2017-09-05 | 2020-03-31 | 中国药科大学 | 咪唑并异吲哚类ido1抑制剂、其制备方法及应用 |
| US20200261414A1 (en) | 2017-09-14 | 2020-08-20 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of cancer |
| EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND USES OF SUCH |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES OF THE LATEST |
| US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| EP3694867A1 (en) | 2017-10-10 | 2020-08-19 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| KR102747388B1 (ko) | 2017-10-16 | 2024-12-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| JP7306634B2 (ja) | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| KR20200074214A (ko) | 2017-11-01 | 2020-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 |
| US11166959B2 (en) | 2017-11-06 | 2021-11-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as HPK1 inhibitors |
| CN111386114A (zh) | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN111886255B (zh) | 2018-01-12 | 2025-04-04 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| JP7217279B2 (ja) | 2018-01-15 | 2023-02-02 | イドーシア ファーマシューティカルズ リミテッド | インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤 |
| CN111247119B (zh) * | 2018-01-19 | 2023-02-03 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| US10793563B2 (en) | 2018-01-29 | 2020-10-06 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| KR20200116481A (ko) | 2018-01-29 | 2020-10-12 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| MX2020008791A (es) | 2018-02-23 | 2021-01-08 | Bicycletx Ltd | Ligandos de peptidos biciclicos multimericos. |
| KR20200130362A (ko) | 2018-03-08 | 2020-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| AU2019239747A1 (en) | 2018-03-21 | 2020-10-08 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| CN112218657A (zh) | 2018-04-12 | 2021-01-12 | 百时美施贵宝公司 | Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法 |
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| ES2950007T3 (es) | 2018-06-27 | 2023-10-04 | Bristol Myers Squibb Co | Compuestos de naftiridinona útiles como activadores de células T |
| BR112020026681A2 (pt) | 2018-06-27 | 2021-04-06 | Bristol-Myers Squibb Company | Compostos naftiridinona substituídos úteis como ativadores de célula t |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| BR112021000303A2 (pt) | 2018-07-11 | 2021-04-13 | Five Prime Therapeutics, Inc. | Anticorpos que se ligam a vista em ph ácido |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP3858813A4 (en) * | 2018-09-27 | 2022-06-22 | Shenzhen Chipscreen Biosciences Co., Ltd. | QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY |
| CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
| KR20210092769A (ko) | 2018-11-16 | 2021-07-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항-nkg2a 항체 및 그의 용도 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| JP7684947B2 (ja) | 2019-03-19 | 2025-05-28 | フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン | 癌の治療のための併用療法 |
| US20220184222A1 (en) | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US20230295087A1 (en) | 2019-05-13 | 2023-09-21 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| EP3997083A1 (en) | 2019-07-11 | 2022-05-18 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| EP4027995A4 (en) | 2019-09-13 | 2023-08-23 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND THEIR APPLICATIONS |
| EP4031575A1 (en) | 2019-09-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| KR20220103753A (ko) | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| CA3159071A1 (en) | 2019-11-26 | 2021-06-03 | Tamar I. ROSENBAUM | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| CN111333653A (zh) * | 2019-12-16 | 2020-06-26 | 山东大学 | 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| MX2022007576A (es) | 2019-12-17 | 2022-09-23 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294273A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds are useful as t-cell activators |
| IL294150A (en) | 2019-12-23 | 2022-08-01 | Kymera Therapeutics Inc | Smarca joints and their uses |
| BR112022012222A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Derivados de piperazina substituídos úteis como ativadores de células t |
| IL294269A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| ES3038401T3 (en) | 2019-12-23 | 2025-10-13 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds useful as t cell activators |
| CA3166898A1 (en) | 2020-01-06 | 2021-07-15 | Hifibio (Hk) Limited | Anti-tnfr2 antibody and uses thereof |
| BR112022013494A2 (pt) | 2020-01-07 | 2022-09-13 | Hifibio Hk Ltd | Anticorpo anti-galectina-9 e usos do mesmo |
| EP4090663A1 (en) | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| US20230140384A1 (en) | 2020-03-09 | 2023-05-04 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| CN111803635B (zh) * | 2020-06-17 | 2023-03-14 | 中国医学科学院基础医学研究所 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| KR20230044480A (ko) | 2020-07-30 | 2023-04-04 | 카이메라 쎄라퓨틱스 인코포레이티드 | 돌연변이 림프종의 치료 방법 |
| IL300537A (en) | 2020-08-10 | 2023-04-01 | Gv20 Therapeutics Llc | Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8 |
| EP4196792A1 (en) | 2020-08-17 | 2023-06-21 | BicycleTX Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CA3200814A1 (en) | 2020-12-02 | 2022-06-09 | Alfredo C. Castro | Tead inhibitors and uses thereof |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN116964050A (zh) | 2020-12-16 | 2023-10-27 | 戈萨默生物服务公司 | 可用作t细胞激活剂的化合物 |
| AU2021413371A1 (en) | 2020-12-30 | 2023-07-13 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| AU2022215844A1 (en) | 2021-02-02 | 2023-09-14 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN117098757A (zh) | 2021-02-02 | 2023-11-21 | 里米诺生物科学有限公司 | Gpr84拮抗剂和其用途 |
| WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| CN117120090A (zh) | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| AU2022221124A1 (en) | 2021-02-12 | 2023-08-03 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022220869A1 (en) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024510176A (ja) | 2021-03-08 | 2024-03-06 | ブループリント メディシンズ コーポレイション | Ｍａｐ４ｋ１阻害剤 |
| US11918582B2 (en) | 2021-03-15 | 2024-03-05 | Rapt Therapeutics, Inc. | Pyrazole pyrimidine compounds and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| MX2023011408A (es) | 2021-04-05 | 2024-01-18 | Bristol Myers Squibb Co | Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer. |
| AR125298A1 (es) | 2021-04-06 | 2023-07-05 | Bristol Myers Squibb Co | Compuestos de oxoisoindolina sustituidos con piridinilo |
| EP4319756A4 (en) | 2021-04-09 | 2025-02-26 | Nimbus Clio, Inc. | CBL-B MODULATORS AND USES THEREOF |
| JP2024514879A (ja) | 2021-04-16 | 2024-04-03 | イケナ オンコロジー， インコーポレイテッド | Ｍｅｋ阻害剤及びその使用 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| AU2022312496A1 (en) | 2021-07-14 | 2024-02-22 | Blueprint Medicines Corporation | Heterocyclic compounds as map4k1 inhibitors |
| TW202321238A (zh) | 2021-07-15 | 2023-06-01 | 美商纜圖藥品公司 | Ｍａｐ４ｋ１抑制劑 |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| CN118302168A (zh) | 2021-10-29 | 2024-07-05 | 凯麦拉医疗公司 | Irak4降解剂和其制备 |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2025503312A (ja) | 2022-02-01 | 2025-01-30 | アルビナス・オペレーションズ・インコーポレイテッド | Ｄｇｋ標的化化合物およびその使用 |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| IL318576A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | Pyridoxine-substituted GPR84 antagonists and their uses |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
| WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
| TW202417439A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
| WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
| MA71728A (fr) | 2022-08-11 | 2025-05-30 | F. Hoffmann-La Roche Ag | Dérivés bicycliques de tétrahydrothiazépine |
| JP2025526727A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| US20240208961A1 (en) | 2022-11-22 | 2024-06-27 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| CN116143726B (zh) * | 2022-12-02 | 2024-09-06 | 广州市联瑞制药有限公司 | 一种环磷腺苷杂质的制备方法 |
| WO2024137865A1 (en) | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| CN121057732A (zh) | 2023-05-08 | 2025-12-02 | 百时美施贵宝公司 | 经取代的苯基噁唑酮化合物 |
| AU2024269298A1 (en) | 2023-05-10 | 2025-11-27 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
| WO2024249540A1 (en) | 2023-05-31 | 2024-12-05 | Bristol-Myers Squibb Company | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins |
| WO2024254227A1 (en) | 2023-06-07 | 2024-12-12 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| WO2024263853A1 (en) | 2023-06-23 | 2024-12-26 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| WO2024264017A2 (en) | 2023-06-23 | 2024-12-26 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| AR133696A1 (es) | 2023-09-02 | 2025-10-22 | Bristol Myers Squibb Co | Compuestos de fenil oxooxazolil piperidinadiona sustituida |
| TW202525792A (zh) | 2023-09-13 | 2025-07-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物 |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| US20250145590A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096489A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096490A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| CN119707950A (zh) * | 2024-12-24 | 2025-03-28 | 无锡市南京大学锡山应用生物技术研究所 | 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4584013A (en) | 1983-05-18 | 1986-04-22 | Ciba-Geigy Corporation | Cyclohexanedionecarboxylic acid derivatives with herbicidal and plant growth regulating properties |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| AU1628699A (en) | 1997-12-05 | 1999-06-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| US20030194803A1 (en) | 2002-04-12 | 2003-10-16 | Mellor Andrew L. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| EP1606285A4 (en) | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION PROCEDURES |
| US7598287B2 (en) | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| DK2559690T3 (en) * | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
| US7705022B2 (en) | 2005-10-27 | 2010-04-27 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| EP2137168B1 (en) | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
| CA2932121A1 (en) * | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| CA2709202C (en) | 2007-12-19 | 2013-04-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| NZ590268A (en) | 2008-07-08 | 2012-11-30 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| NO2694640T3 (enExample) * | 2011-04-15 | 2018-03-17 | ||
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| EA201591610A1 (ru) | 2013-03-14 | 2015-12-30 | Курадев Фарма Прайвит Лтд. | Ингибиторы кинуренинового пути |
| BR112015022588A2 (pt) | 2013-03-14 | 2017-07-18 | Newlink Genetics Corp | composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| BR112015021999A8 (pt) | 2013-03-15 | 2019-12-03 | Bristol Myers Squibb Co | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase |
| MA38483A1 (fr) | 2013-03-15 | 2018-02-28 | Bristol Myers Squibb Co | Inhibiteurs de l'ido |
| JP2016528197A (ja) | 2013-07-01 | 2016-09-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| WO2015006520A1 (en) | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
-
2012
- 2012-04-05 NO NO12767723A patent/NO2694640T3/no unknown
- 2012-04-12 ME MEP-2016-82A patent/ME02417B/me unknown
- 2012-04-12 NZ NZ708090A patent/NZ708090A/en unknown
- 2012-04-12 BR BR112013026494A patent/BR112013026494A2/pt not_active Application Discontinuation
- 2012-04-12 DK DK12715295.7T patent/DK2697227T3/en active
- 2012-04-12 ES ES15197593.5T patent/ES2660831T3/es active Active
- 2012-04-12 CA CA2833296A patent/CA2833296C/en active Active
- 2012-04-12 HR HRP20160369TT patent/HRP20160369T1/hr unknown
- 2012-04-12 PL PL15197593T patent/PL3018132T3/pl unknown
- 2012-04-12 WO PCT/US2012/033245 patent/WO2012142237A1/en not_active Ceased
- 2012-04-12 RU RU2013150811A patent/RU2613579C2/ru active
- 2012-04-12 JP JP2014505274A patent/JP2014511876A/ja not_active Withdrawn
- 2012-04-12 RU RU2017107026A patent/RU2017107026A/ru unknown
- 2012-04-12 DK DK15197593.5T patent/DK3018132T3/en active
- 2012-04-12 HU HUE12715295A patent/HUE027316T2/en unknown
- 2012-04-12 SI SI201231193T patent/SI3018132T1/en unknown
- 2012-04-12 RS RS20160285A patent/RS54723B1/sr unknown
- 2012-04-12 EP EP17205515.4A patent/EP3348558A1/en not_active Withdrawn
- 2012-04-12 ES ES12715295.7T patent/ES2569665T3/es active Active
- 2012-04-12 EP EP15197593.5A patent/EP3018132B1/en active Active
- 2012-04-12 PT PT151975935T patent/PT3018132T/pt unknown
- 2012-04-12 PE PE2017002751A patent/PE20181023A1/es not_active Application Discontinuation
- 2012-04-12 RS RS20180223A patent/RS56992B1/sr unknown
- 2012-04-12 NZ NZ723271A patent/NZ723271A/en unknown
- 2012-04-12 HU HUE15197593A patent/HUE038586T2/hu unknown
- 2012-04-12 EP EP12715295.7A patent/EP2697227B1/en active Active
- 2012-04-12 LT LTEP15197593.5T patent/LT3018132T/lt unknown
- 2012-04-12 CN CN201280018684.7A patent/CN103547579B/zh active Active
- 2012-04-12 AU AU2012242871A patent/AU2012242871C1/en active Active
- 2012-04-12 KR KR1020137030438A patent/KR102164443B1/ko active Active
- 2012-04-12 SI SI201230515A patent/SI2697227T1/sl unknown
- 2012-04-12 CN CN201510262906.5A patent/CN105111210B/zh active Active
- 2012-04-12 MX MX2013012021A patent/MX340442B/es active IP Right Grant
- 2012-04-12 PL PL12715295.7T patent/PL2697227T3/pl unknown
- 2012-04-12 PE PE2013002332A patent/PE20141124A1/es active IP Right Grant
-
2013
- 2013-10-14 US US14/053,440 patent/US9260434B2/en active Active
- 2013-10-14 IL IL228862A patent/IL228862A/en active IP Right Grant
- 2013-10-15 CL CL2013002990A patent/CL2013002990A1/es unknown
- 2013-11-14 CO CO13268287A patent/CO6862146A2/es active IP Right Grant
-
2014
- 2014-12-10 AU AU2014274564A patent/AU2014274564B2/en active Active
- 2014-12-22 JP JP2014258630A patent/JP5837673B2/ja active Active
-
2015
- 2015-07-08 US US14/794,193 patent/US9388191B2/en active Active
- 2015-09-24 IL IL241846A patent/IL241846A/en active IP Right Grant
- 2015-11-05 JP JP2015217361A patent/JP6145491B2/ja active Active
-
2016
- 2016-04-27 CY CY20161100355T patent/CY1117440T1/el unknown
- 2016-05-04 SM SM201600130T patent/SMT201600130B/it unknown
- 2016-06-13 US US15/181,062 patent/US9850248B2/en active Active
- 2016-06-28 IL IL246515A patent/IL246515B/en active IP Right Grant
- 2016-12-20 AU AU2016277574A patent/AU2016277574B2/en active Active
-
2017
- 2017-05-15 JP JP2017096307A patent/JP2017149769A/ja not_active Withdrawn
- 2017-11-01 US US15/800,190 patent/US10233190B2/en active Active
-
2018
- 2018-02-26 HR HRP20180335TT patent/HRP20180335T1/hr unknown
- 2018-04-18 AU AU2018202706A patent/AU2018202706A1/en not_active Abandoned
- 2018-12-03 HK HK18115442.2A patent/HK1256355A1/en unknown
-
2019
- 2019-02-07 US US16/269,681 patent/US20190225618A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| US11130738B2 (en) | Pharmaceutical compound | |
| AU2015239886B2 (en) | Indole derivatives for use in medicine | |
| RU2744988C2 (ru) | Соединения и композиции для подавления активности shp2 | |
| EP3082802B1 (en) | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use | |
| CN109562106B (zh) | Cxcr4抑制剂及其用途 | |
| US10287252B2 (en) | Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase | |
| US10047074B2 (en) | Pharmaceutical compound | |
| TWI696618B (zh) | 用於合成吲哚胺2,3-雙加氧酶抑制劑之方法 | |
| JP2013512903A5 (enExample) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| CN118684661A (zh) | 杂芳基类化合物及其药物组合物、制备方法和用途 | |
| JPH10316563A (ja) | 原生動物感染の治療方法 | |
| US10858319B2 (en) | Indole derivatives for use in medicine | |
| CN120025367A (zh) | 一类磷酸烯醇化合物及其制备方法和在机体炎症性疾病中的应用 | |
| EP4629986A1 (en) | Treatment of graft-versus-host disease with inhibitors of bet family bdii bromodomain | |
| RU2014122338A (ru) | Неконкурентные модуляторы никотиновых рецепторов | |
| HK1226725B (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis | |
| HK1226725A1 (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |